zurück

Luspatercept (re-assessment, 30 M € limit exceeded: myelodysplastic syndromes (MDS) with transfusion-dependent anemia, pretreated patients)

 

Subject:

  • Active Substance: Luspatercept
  • Name: Reblozyl®
  • Therapeutic area: Myelodysplastic syndromes (MDS)
  • Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

 

Time table:

  • Start: 15.05.2023
  • Publication of assessment: 15.08.2023
  • End of public hearing: 05.09.2023
  • Final decision by G-BA: beginning of November 2023

 

Comparative therapy:

  • Transfusion therapy with red blood cell concentrates as required in combination with chelation therapy according to the approval